June 15, 2018 / 6:44 AM / 3 months ago

BRIEF-Roche says 5-year analysis shows survival benefit with Gazyva vs Mabthera

June 15 (Reuters) - Roche Holding AG:

* SAYS NEW LONG-TERM DATA CONFIRM ROCHE'S GAZYVA/GAZYVARO EXTENDS LIVES OF PEOPLE WITH CHRONIC LYMPHOCYTIC LEUKAEMIA COMPARED TO MABTHERA/RITUXAN

* SAYS CLL11 STUDY SHOWS A 51% REDUCTION IN RISK OF DISEASE PROGRESSION OR DEATH WITH GAZYVA/GAZYVARO COMPARED TO MABTHERA/RITUXAN

* SAYS ANALYSIS REPORTS A CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT IS SEEN FOR GAZYVA/GAZYVARO COMPARED TO MABTHERA/RITUXAN WHEN COMBINED WITH CHLORAMBUCIL Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below